Annovis Bio Gains U.S. Patent for Acute Traumatic Brain Injury Treatment with Buntanetap

On July 24, 2024, Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company dedicated to developing transformative therapies for neurodegenerative disorders, announced the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) using its leading drug candidate, buntanetap.

The journey to this patent began in 2016 when the Company filed a patent covering the treatment of various nerve insults, including TBI, stroke, and spinal cord injuries. Although these claims were approved in Europe and other global regions, the U.S. Patent and Trademark Office (USPTO) required that the claims be divided into separate patents for each specific indication. Annovis Bio has now secured U.S. Patent No. 12,042,482, which pertains to methods for treating TBI and preventing nerve cell death using buntanetap.

“We are thrilled to achieve this significant milestone for buntanetap,” stated Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s. Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”

This patent significantly enhances Annovis Bio’s portfolio, which includes various patents and applications covering the use of buntanetap for both acute and chronic neurodegenerative diseases as well as mental illnesses. The Company's commitment to addressing a wide array of neurodegenerative disorders underscores its innovative approach to restoring brain function and improving patient outcomes.

Buntanetap, previously known as Posiphen or ANVS401, targets neurodegeneration by inhibiting the formation of several neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This leads to improved synaptic transmission, axonal transport, and a reduction in neuroinflammation. Dysregulation of these pathways has been linked to nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap holds the potential to reverse neurodegeneration in disorders such as Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and enhance patients' quality of life.

Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is dedicated to tackling neurodegeneration in diseases like Alzheimer’s and Parkinson’s. The company’s innovative approach targets multiple neurotoxic proteins with the goal of restoring brain function and improving the quality of life for patients.